|
|
 |
|
Viewing report
|
|
|
|
2010 State of Rheumatology Special Report, "The Payer Perspective on the Most Pertinent Issues in Rheumatology, Including Reactions to Key Clinical and Economic Data Presentations at the 2010 ACR Scientific Meeting"
Reimbursement Intelligence, Dec 2010, Pages: 250
Rheumatology is a dynamic and evolving therapeutic area high on the radar of Commercial and Government Payers. With the proliferation of biologics and products that rely on personalized medicine, the rheumatology market landscape continues to evolve rapidly. Payers are increasing their focus on management of therapies in high cost categories like rheumatoid arthritis, osteoporosis, osteoarthritis, and psoriatic arthritis by implementing controls to ensure appropriate utilization and minimization of cost. This focus on cost-minimization presents significant challenges for manufacturers with both current and pipeline products.
The Reimbursement IQ (RIQ): 2010 State of Rheumatology Special Report provides comprehensive analysis of key targeted therapeutic are astherapeutic areas, including rheumatoid arthritis, osteoporosis, osteoarthritis, psoriatic arthritis, and other critical disease states. This insightful report will uncover Payer decision-makers’ perspectives across a wide range of topics, including:
Market Landscape Assessment
- Treatment algorithm evaluation including assessment of perceived points of differentiation and “value story” of existing treatments Management of Current
Treatment Options
- Assessment of formulary status for current treatment options
Perception of Unmet Needs
- Clinical endpoints as well as economic factors
Future Market Trends and Expectations
- Expectations for changes in market landscape including scenario and price sensitivity analysis
Evaluation of New Market Entrants
- Clinical and economic value assessment based on the latest clinical trial data presented at ACR
This insightful report will uncover Payer decision-makers' perspectives across a wide range of topics:
- Market Landscape Assessment
- Management of Current Treatment Options
- Perception of Unmet Needs
- Future Market Trends and Expectations
- Evaluation of New Market Entrants
Methodology
Reimbursement Intelligence will conduct the Reimbursement IQ: 2010 State of Rheumatology Special Report survey following the close of the ACR meeting on November 6-11, 2010 in Atlanta, Georgia. The survey will be fielded to 50 Medical and Pharmacy Directors, representing the largest national and regional
Commercial/Medicare plans and Medicaid states.
- Purchasers have the opportunity to add confidential and/or proprietary questions about any area or product relevant to rheumatology
- Reimbursement Intelligence will provide an in-person presentation of the results for purchasing companies
Why Purchase the Reimbursement IQ: 2010 State of Rheumatology Special Report?
- Understand the current and future market landscape of the targeted therapy areas from a reimbursement and market access perspective
- Gauge level of perceived clinical and economic unmet needs
- Gain insight into the payers’ approach to management of current and pipeline products
|
|
|
|
